Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib Induction in Crohn's Disease (U-EXCEED)
NCT03345836Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2017
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 48
01
Overview
A Phase 3 trial of upadacitinib in Crohn's disease, sponsored by AbbVie Inc.. Started Nov 2017; status: completed.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03345836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03345836.